BeyondSpring (BYSI) Q2 2026 loss narrows as Plinabulin data and DUBLIN-4 plans advance

Rhea-AI Filing Summary

BeyondSpring Inc. reported second-quarter 2026 results and highlighted new clinical data for its lead asset, Plinabulin, in metastatic non-small cell lung cancer (NSCLC). Updated Phase 2 ASCO 2026 data showed a 58.0% two-year overall survival (OS) rate in post–immune checkpoint inhibitor patients, with median progression-free survival of 7.0 months and a generally manageable safety profile. Preclinical AACR 2026 data suggested Plinabulin may enhance the efficacy and tolerability of certain antibody-drug conjugates.

The company is preparing DUBLIN-4, a planned 442-patient confirmatory Phase 3 study of Plinabulin plus docetaxel in non-squamous, EGFR wild-type NSCLC after PD-1/PD-L1 therapy. A leadership transition effective July 1, 2026 installed Min Qiu as Chief Executive Officer, with a mandate focused on advancing DUBLIN-4 and financing activities.

From continuing operations, second-quarter 2026 research and development expenses were $1.0 million, and general and administrative expenses were $0.8 million, leading to a net loss of $1.8 million. For the six months ended June 30, 2026, net loss from continuing operations was $4.1 million. Cash, cash equivalents, and short-term investments totaled $6.5 million as of June 30, 2026, while total liabilities were $50.6 million against total assets of $14.6 million, resulting in a shareholders’ deficit.

Positive

• Encouraging Phase 2 survival data for Plinabulin/docetaxel and pembrolizumab in metastatic NSCLC post-ICI, including a 58.0% two-year OS rate and median progression-free survival of 7.0 months, supports continued late-stage development.
• Clear late-stage development plan with the planned 442-patient confirmatory DUBLIN-4 Phase 3 trial in NSCLC post-ICI provides a defined path toward potential future regulatory submissions for Plinabulin.

Negative

• Liquidity is constrained, with $6.5 million in cash, cash equivalents, and short-term investments at June 30, 2026, down from $12.6 million at December 31, 2025, while the company continues to incur operating losses.
• The balance sheet shows total liabilities of $50.6 million versus total assets of $14.6 million, resulting in a total shareholders’ deficit of $36.0 million (in thousands), underscoring a highly leveraged capital structure.
• There was no revenue reported for the three- and six-month periods ended June 30, 2026, and net loss from continuing operations was $4.1 million year-to-date, reflecting ongoing cash burn without offsetting operating income.

Filing Explained

At June 30, 2026, liquidity was $2,697 thousand cash plus $3,832 thousand short-term investments; second-quarter consolidated loss was $5,700 thousand.

This Form 8-K is a completed report of BeyondSpring’s quarter ended June 30, 2026 results, furnished through Exhibit 99.1 rather than a transaction report; the release is not treated as filed under Section 18 or incorporated into other filings except by express reference.

An 8-K reports specified material events within four business days, with item numbers identifying the event category.

At June 30, 2026, the reported $6.5 million of liquidity consisted of $2,697 thousand in cash and cash equivalents and $3,832 thousand in short-term investments.

The quarter’s $5,700 thousand consolidated net loss included a $3,950 thousand loss from discontinued operations; continuing-operations net loss was $1,750 thousand.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Cash, cash equivalents and short-term investments: $6.5 million Total assets: $14.6 million Total liabilities: $50.6 million +5 more

8 metrics

Cash, cash equivalents and short-term investments $6.5 million As of June 30, 2026, from continuing operations disclosure

Total assets $14.6 million Total assets as of June 30, 2026 (amounts in thousands)

Total liabilities $50.6 million Total liabilities as of June 30, 2026 (amounts in thousands)

Shareholders’ deficit $36.0 million Total shareholders’ deficit of 36,025 (in thousands) at June 30, 2026

Q2 2026 net loss from continuing operations $1.8 million Three months ended June 30, 2026

Six-month net loss from continuing operations $4.1 million Six months ended June 30, 2026

Two-year overall survival rate 58.0% Phase 2 ASCO 2026 Plinabulin/docetaxel and pembrolizumab study in metastatic NSCLC post-ICI

Planned DUBLIN-4 enrollment 442 patients Planned confirmatory Phase 3 NSCLC study of Plinabulin plus docetaxel

Key Terms

metastatic NSCLC, antibody-drug conjugates, progression-free survival, overall survival, +2 more

6 terms

metastatic NSCLC medical

"in metastatic NSCLC patients whose disease progressed after first-line immune"

Metastatic NSCLC is non-small cell lung cancer that has spread beyond the lungs to other organs; 'non-small cell' describes the most common group of lung cancers while 'metastatic' means the disease is advanced and no longer confined to its original site. It matters to investors because spread disease creates urgent demand for new therapies, longer and riskier clinical programs, larger potential markets for effective drugs, and greater regulatory and pricing pressure—like a small fire that has jumped rooms and requires more complex firefighting.

antibody-drug conjugates medical

"as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)"

A class of targeted cancer medicines that combine a lab-made antibody (which finds and sticks to specific markers on tumor cells) with a powerful cell-killing drug linked together so the toxic payload is delivered directly to the tumor. Think of it like a guided missile that reduces collateral damage compared with traditional chemotherapy; for investors, success or failure of these drugs drives clinical, regulatory and commercial value and can sharply affect a biotech company’s prospects and stock price.

progression-free survival medical

"median progression-free survival was 7.0 months, median duration of response"

Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.

overall survival medical

"The 12-month and 24-month overall survival rates were 78.1% and 58.0%"

Overall survival is the average or median length of time patients remain alive after starting a treatment or entering a clinical study, measured regardless of cause of death. Investors care because it is a clear, hard measure of a therapy’s real-world benefit — like timing how long a new battery actually runs — and strong improvements in overall survival can drive regulatory approval, market adoption and revenue potential.

discontinued operations financial

"Net loss from continuing operations and Loss from discontinued operations"

Discontinued operations are parts of a company that it has decided to sell or shut down, and no longer plans to run in the future. This matters to investors because it helps them understand which parts of the business are ongoing and which are being phased out, providing a clearer picture of the company’s current performance and future prospects. Think of it like a store closing a department—it no longer contributes to sales or profits.

deferred revenue financial

"Deferred revenue | 28,600 | | | | 29,476 |"

Cash a company has already received for goods or services it has promised but not yet delivered; it's recorded as a liability because the company still owes that product, service, or future revenue recognition. For investors, deferred revenue signals upcoming work or deliveries that will convert into reported sales over time and affects short-term obligations, cash flow quality, and how quickly a firm can grow recognized revenue—think of it like prepaid subscriptions or gift cards a business must honor later.

Earnings Snapshot

Net loss from continuing operations (Q2): $1.8 million

quarter ended June 30, 2026

Net loss from continuing operations (Q2) $1.8 million $1.8 million in Q2 2026 vs $1.9 million in Q2 2025

R&D expenses (Q2) $1.0 million $1.0 million in both Q2 2026 and Q2 2025

G&A expenses (Q2) $0.8 million $0.8 million in Q2 2026 vs $0.9 million in Q2 2025

Net loss from continuing operations (six months) $4.1 million $4.1 million for six months 2026 vs $4.5 million for six months 2025

FAQ

What were BeyondSpring (BYSI) second-quarter 2026 financial results from continuing operations?

BeyondSpring reported a Q2 2026 net loss from continuing operations of $1.8 million on $1.0 million R&D and $0.8 million G&A expenses, with no revenue recognized. Year-to-date, net loss from continuing operations was $4.1 million.

How much cash does BeyondSpring (BYSI) have as of June 30, 2026?

As of June 30, 2026, BeyondSpring held $6.5 million in cash, cash equivalents, and short-term investments. This compares with $12.6 million at December 31, 2025, indicating a significant decline in liquidity over the first half of 2026.

What key clinical results for Plinabulin did BeyondSpring (BYSI) highlight in Q2 2026?

BeyondSpring highlighted updated Phase 2 ASCO 2026 data in metastatic NSCLC post-ICI, including a 58.0% two-year overall survival rate, 7.0-month median progression-free survival, 9.3-month median duration of response, and a 79.5% disease control rate with a generally manageable safety profile.

What is BeyondSpring’s (BYSI) DUBLIN-4 Phase 3 program?

DUBLIN-4 is a planned 442-patient, randomized, double-blind confirmatory Phase 3 study of Plinabulin plus docetaxel in non-squamous, EGFR wild-type NSCLC patients who have progressed on PD-1/PD-L1 inhibitor-containing therapies, aiming to prospectively confirm survival and tolerability benefits.

How did BeyondSpring’s (BYSI) operating expenses change year-to-date in 2026?

For the six months ended June 30, 2026, R&D expenses were $2.0 million versus $1.9 million a year earlier, while G&A expenses fell to $1.9 million from $2.7 million, mainly due to lower incentive, share-based compensation, and professional service costs.

What is BeyondSpring’s (BYSI) overall balance sheet position at June 30, 2026?

At June 30, 2026, BeyondSpring reported total assets of $14.6 million and total liabilities of $50.6 million, resulting in a total shareholders’ deficit of $36.0 million (amounts in thousands), reflecting a negative equity position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Available on EDGAR 08/14/2026 - 05:15 PM Accepted by SEC EDGAR 08/14/2026 - 05:15 PM Learn about SEC filing dates

False000167794000016779402026-08-142026-08-14iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  August 14, 2026

_______________________________

BeyondSpring Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Cayman Islands	001-38024	Not Applicable
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

100 Campus Drive, West Side, 4th Floor, Suite 410

Florham Park, New Jersey 07932

(Address of Principal Executive Offices) (Zip Code)

+1 (646) 305-6387

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Ordinary Shares, par value $0.0001 per share	BYSI	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 14, 2026, BeyondSpring Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information provided in this Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press release, dated August 14, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BeyondSpring Inc.
Date: August 14, 2026	By:	/s/ Min Qiu
		Min Qiu
		Chief Executive Officer

EXHIBIT 99.1

BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update

ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on First-Line Immune Checkpoint Inhibitor (ICI) Therapy

AACR 2026 Preclinical Data Provide the Scientific Rationale for Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC) Regimens to Improve Efficacy, Survival and Tolerability

Leadership Transition Effective July 1, 2026 Aligns the Organization Around Focused Advancement of the Confirmatory DUBLIN-4 Program in NSCLC Post-ICI and Long-Term Value Creation

FLORHAM PARK, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced its financial results for the quarter ended June 30, 2026, and provided a corporate update highlighting clinical progress for Plinabulin and the Company’s leadership transition.

“The second quarter was marked by additional clinical and scientific support for continuing Plinabulin development,” said Min Qiu, Chief Executive Officer of BeyondSpring. “Updated Phase 2 data presented at ASCO 2026 continued to demonstrate an encouraging 58% two-year OS rate in metastatic NSCLC patients whose disease progressed after first-line immune checkpoint inhibitor (ICI) therapy. This encouraging prospective OS data strengthens our conviction in the DUBLIN-4 study, a confirmatory Phase 3 study with OS as the primary endpoint in non-squamous NSCLC post-ICI with no driver mutation, a severe unmet medical need with docetaxel as the standard of care. With our leadership transition now effective, our priorities are clear: advancing the regulatory, operational and financing preparations necessary to initiate DUBLIN-4.”

Mr. Qiu continued, “The DUBLIN-4 study represents our lead clinical development priority for a potential path toward future regulatory submissions. We believe the published DUBLIN-3 results in The Lancet Respiratory Medicine, recent ASCO 2026 clinical data, and the AACR 2026 ADC combination findings collectively reinforce Plinabulin’s differentiated potential as a potent dendritic cell maturation agent to improve survival benefits while mitigating treatment-limiting high-grade neutropenia in NSCLC and beyond.”

Recent Clinical and Corporate Highlights of Plinabulin

ASCO 2026 (Phase 2 data): Plinabulin combination demonstrated durable response and survival benefit in post-ICI metastatic NSCLC

• Presented updated efficacy and safety results from the investigator-initiated Phase 2 303 Study evaluating Plinabulin/docetaxel and pembrolizumab in 47 patients with metastatic NSCLC and acquired resistance following first-line immune checkpoint inhibitor therapy.
• As of the February 28, 2026 data cutoff, median progression-free survival was 7.0 months, median duration of response was 9.3 months, disease control rate was 79.5%, and confirmed objective response rate was 18.2%.
• The 12-month and 24-month overall survival rates were 78.1% and 58.0%, respectively, with median overall survival not reached after a median follow-up of 28.8 months.
• The combination demonstrated a generally manageable safety profile and evidence of immune activation, including increased frequencies of activated CD4+ and CD8+ T cells as well as higher white blood cell, neutrophil, and platelet counts.

AACR 2026 (preclinical data): Improved complete response rate, overall survival and tolerability of certain antibody-drug-conjugates (ADCs)

• Presented preclinical data showing that Plinabulin in combination with the approved topoisomerase I inhibitor (TOP1)-based ADCs enhanced complete tumor regression rates and/or survival of TROP-2-directed datopotamab deruxtecan or HER2-directed trastuzumab deruxtecan, with or without PD-1/PD-L1 inhibition.
• Plinabulin improved tolerability in the preclinical combination models and increased the CD8+ T-cell-to-Treg ratio, supporting an immune-mediated mechanism for the enhanced anticancer activity.
• The findings support Plinabulin’s potential to address limited durability and treatment-limiting hematologic toxicity associated with ADC-based therapy and broaden the scientific rationale for future ADC combination studies.
  

DUBLIN-4 Confirmatory Phase 3 Program

• DUBLIN-4 is the Company’s planned, randomized, double-blind, 442-patient confirmatory Phase 3 study of Plinabulin plus docetaxel in non-squamous, EGFR wild-type NSCLC patients who have progressed on PD-1/PD-L1 inhibitor-containing therapies.
• The program is designed to prospectively confirm the survival and tolerability benefits observed in the DUBLIN-3 Phase 3 study, which was published in The Lancet Respiratory Medicine in 2024.

BeyondSpring Leadership Transition and Corporate Execution

• Effective July 1, 2026, Min Qiu was appointed Chief Executive Officer with a mandate focused on advancing DUBLIN-4, extending Plinabulin’s scientific optionality, and building BeyondSpring’s global partner and investor base. Dr. Jiangwen (Jen) Majeti was appointed Vice Chairman, strengthening Board-level governance continuity and strategic depth. Na Li was appointed Chief Financial Officer to support financial discipline, public-company reporting, financing activities, and capital markets engagement.
• Dr. Lan Huang remains Co-Founder and Chairman of BeyondSpring, providing strategic vision and Board leadership, while devoting her executive focus to SEED Therapeutics, where she serves as Co-Founder, Chairman, and Chief Executive Officer.

Second Quarter Financial Results

Continuing operations:

• Research and development (R&D) expenses were $1.0 million for the quarter ended June 30, 2026, compared to $1.0 million for the quarter ended June 30, 2025. R&D expenses remained relatively flat, as a $0.3 million increase in drug manufacturing activities to prepare for potential future study initiation was substantially offset by lower patent-related professional services and personnel expenses.
• General and administrative (G&A) expenses were $0.8 million for the quarter ended June 30, 2026, compared to $0.9 million for the quarter ended June 30, 2025. The $0.1 million decrease was primarily due to lower legal and consulting expenses related to accounting advisory and business development.
• Net loss was $1.8 million for the quarter ended June 30, 2026, compared to $1.9 million for the quarter ended June 30, 2025.
• Cash, cash equivalents, and short-term investments were $6.5 million as of June 30, 2026, compared to $12.6 million as of December 31, 2025.

Year-to-Date Financial Results

Continuing operations:

• Research and development (R&D) expenses were $2.0 million for the six months ended June 30, 2026, compared to $1.9 million for the six months ended June 30, 2025. The $0.1 million increase was primarily due to higher drug manufacturing expenses, partially offset by lower patent-related professional services, regulatory filing advisory and personnel expenses.
• General and administrative (G&A) expenses were $1.9 million for the six months ended June 30, 2026, compared to $2.7 million for the six months ended June 30, 2025. The $0.8 million decrease was primarily due to lower incentive compensation and share-based compensation and lower professional services expenses related to legal advisory matters.
• Net loss was $4.1 million for the six months ended June 30, 2026, compared to $4.5 million for the six months ended June 30, 2025.
  

About BeyondSpring

BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies for cancers with high unmet needs. Its lead asset, Plinabulin, has been studied in over 700 cancer patients and is in late-stage development across multiple cancer indications, with results published in The Lancet Respiratory Medicine. Plinabulin’s novel mechanism as a GEF-H1 agonist with dendritic cell maturation benefit supports both anticancer activity and immune modulation, offering a unique approach to re-sensitizing tumors resistant to checkpoint inhibitors. In addition, it has the potential to synergize with chemotherapy, antibody-drug conjugates (ADCs), radiation, and checkpoint inhibitors. Learn more at beyondspringpharma.com.

Investor Contact: IR@beyondspringpharma.com
Media Contact: PR@beyondspringpharma.com

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements that are not historical facts. Words such as “will,” “expect,” “anticipate,” “plan,” “believe,” “design,” “may,” “future,” “estimate,” “predict,” “objective,” “goal,” or variations thereof and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring’s current knowledge, beliefs, and expectations regarding possible future events and are subject to risks, uncertainties, and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including, but not limited to, difficulties raising the anticipated amount needed to finance the Company’s future operations on terms acceptable to the Company, if at all; unexpected results from preclinical studies or clinical trials; the risk that preclinical results may not be predictive of clinical results; delays in, or failure to obtain, regulatory approvals; results that do not meet the Company’s expectations regarding the safety, efficacy, clinical utility, or regulatory pathway of the Company’s product candidates; increased competition in the market; the Company’s ability to meet Nasdaq’s continued listing requirements; and other risks described in BeyondSpring’s most recent Form 10-K and subsequent filings with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release, and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Financial Tables to Follow

BEYONDSPRING INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands of U.S. Dollars (“$”), except for number of shares and per share data)
		As of
		December 31, 2025				June 30, 2026
			$				$
						(Unaudited)
Assets
Current assets:
Cash and cash equivalents			7,786				2,697
Short-term investments			4,775				3,832
Advances to suppliers			227				247
Prepaid expenses and other current assets			71				273
Current assets of discontinued operations			8,023				2,852
Total current assets			20,882				9,901
Noncurrent assets:
Property and equipment, net			166				138
Operating right-of-use assets			305				174
Other noncurrent assets			224				128
Noncurrent assets of discontinued operations			4,356				4,265
Total noncurrent assets			5,051				4,705
Total assets			25,933				14,606
Liabilities and equity
Current liabilities:
Accounts payable			363				790
Accrued expenses			938				1,390
Current portion of operating lease liabilities			320				171
Other current liabilities			822				1,055
Current liabilities of discontinued operations			11,133				10,787
Total current liabilities			13,576				14,193
Noncurrent liabilities:
Deferred revenue			28,600				29,476
Other noncurrent liabilities			3,981				4,420
Noncurrent liabilities of discontinued operations			3,766				2,542
Total noncurrent liabilities			36,347				36,438
Total liabilities			49,923				50,631
Shareholders’deficit
Ordinary shares ($0.0001 par value; 500,000,000 shares authorized; 41,122,320 and 41,119,820 shares issued and outstanding as of December 31, 2025 and June 30, 2026, respectively)			4				4
Additional paid-in capital			375,664				375,814
Accumulated deficit			(408,431	)			(411,439	)
Accumulated other comprehensive income			602				55
Total BeyondSpring Inc.’s shareholders’ deficit			(32,161	)			(35,566	)
Noncontrolling interests			8,171				(459	)
Total shareholders’ deficit			(23,990	)			(36,025	)
Total liabilities and shareholders’deficit			25,933				14,606

BEYONDSPRING INC. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Amounts in thousands of U.S. Dollars (“$”), except for number of shares and per share data) (Unaudited)
		Three months ended June 30,								Six months ended June 30,
		2025				2026				2025				2026
		$				$				$				$
Revenue			-				-				-				-
Operating expenses
Research and development			(1,002	)			(973	)			(1,876	)			(2,049	)
General and administrative			(947	)			(758	)			(2,683	)			(1,914	)
Loss from operations			(1,949	)			(1,731	)			(4,559	)			(3,963	)
Foreign exchange gain, net			47				61				76				111
Interest income			28				4				45				12
Other income, net			18				16				18				31
Loss before income tax			(1,856	)			(1,650	)			(4,420	)			(3,809	)
Income tax expenses			(22	)			(100	)			(42	)			(292	)
Net loss from continuing operations			(1,878	)			(1,750	)			(4,462	)			(4,101	)
Discontinued operations
Loss from discontinued operations			(2,771	)			(3,950	)			(6,003	)			(8,273	)
Gain on sale of subsidiary interests			-				-				6,986				-
Income tax expenses			-				-				-				-
Net income (loss) from discontinued operations			(2,771	)			(3,950	)			983				(8,273	)
Net loss			(4,649	)			(5,700	)			(3,479	)			(12,374	)
Less: Net loss attributable to noncontrolling interests from continuing operations			(72	)			(841	)			(147	)			(973	)
Less: Net loss attributable to noncontrolling interests from discontinued operations			(2,771	)			(4,010	)			(6,003	)			(8,393	)
Net income (loss) attributable to BeyondSpring Inc.			(1,806	)			(849	)			2,671				(3,008	)
Earnings (loss) per share, basic and diluted
Continuing operations			(0.04	)			(0.02	)			(0.11	)			(0.08	)
Discontinued operations			-				-				0.18				-
Basic and diluted earnings (loss) per share			(0.04	)			(0.02	)			0.07				(0.08	)
Weighted-average shares outstanding
Basic and diluted			40,316,320				41,119,820				40,316,320				41,119,820
Other comprehensive loss, net of tax of nil:
Foreign currency translation adjustment loss from continuing operations			(343	)			(471	)			(494	)			(850	)
Foreign currency translation adjustment loss from discontinued operations			(27	)			(70	)			(34	)			(117	)
Comprehensive loss			(5,019	)			(6,241	)			(4,007	)			(13,341	)
Less: Comprehensive loss attributable to noncontrolling interests from continuing operations			(194	)			(1,007	)			(324	)			(1,276	)
Less: Comprehensive loss attributable to noncontrolling interests from discontinued operations			(2,798	)			(4,080	)			(6,037	)			(8,510	)
Comprehensive income (loss) attributable to BeyondSpring Inc.			(2,027	)			(1,154	)			2,354				(3,555	)

Filing Exhibits & Attachments

5 documents

Press Releases

• EX-99.1 PRESS RELEASE 93.8 KB

Other Documents

• EX-101 XBRL SCHEMA FILE 3.3 KB
• EX-101 XBRL DEFINITION FILE 25.5 KB
• EX-101 XBRL LABEL FILE 35.1 KB
• EX-101 XBRL PRESENTATION FILE 24.1 KB